Announcement

Collapse
No announcement yet.

DMT use in the Covid-19 pandemic (Jun 24)

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • DMT use in the Covid-19 pandemic (Jun 24)

    7:00 PM (ET) - WEDNESDAY, June 24th

    Webinar Link: https://event.webcasts.com/starthere...key=73cdfe53ec
    Participant Dial-in: 877-407-9221 or 201-689-8597 (NORTH AMERICA ONLY)

    One hour of continuing education credit is available for physicians, pharmacists, nursing professionals, and PAs.

    TARGET AUDIENCE
    This activity has been designed to meet the educational needs of physicians, pharmacists, nursing professionals, PAs, and other members of the healthcare team involved in the management of patients with MS.

    OBJECTIVE
    Upon completion of this activity, participants should be better able to:

    Identify the latest research and clinical information available describing use of disease modifying therapies in patients with MS during the COVID-19 pandemic.

    MODERATORS
    John F. Kramer, PA-C, Moderator
    STMP Neurology
    Nashville, TN
    Bryan D. Walker, MHS, PA-C, MSCS
    Duke University Medical Center
    Durham, NC

    To view the article click here:
    https://cmscscholar.org/wp-content/u...i-COVID-MS.pdf

    The COVID-19 pandemic and the use of MS disease-modifying therapies Gavin Giovannoni, Chris Hawkes, Jeannette Lechner-Scott, Michael Levy, Emmanuelle Waubant, Julian Gold

    The live webinar is being held on Wednesday, June 24th from 7-8 pm (ET).

    To Register:
    https://event.webcasts.com/starthere...key=73cdfe53ec
    To access the live webinar on the date of the event:
    https://event.webcasts.com/starthere...key=73cdfe53ec
    Participant Dial-In:
    877-407-9221 or 201-689-8597 (NORTH AMERICA ONLY)
    Please test your system a few minutes prior to the webinar:
    System Test Link: http://webcasts.com/test
    For technical support the night of the event, call:
    877-407-0626 or 201-689-7835 (NORTH AMERICA ONLY)

    This activity is supported by educational grants from Celgene Corporation, EMD Serono, Genentech, and Mallinckrodt Pharmaceuticals.
    Dave Bexfield
    ActiveMSers
Working...
X